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PPARs are members of the steroid hormone nuclear receptor superfamily and play an important role in the regulation of lipid
metabolism, energy balance, artherosclerosis and glucose control. Recent studies suggest that they play an important role in
regulatinginﬂammation.ThisreviewwillfocusonPPAR-αregulationoftheimmuneresponse.WedescribehowPPAR-αregulates
diﬀerentiation of T cells by transactivation and/or interaction with other transcription factors. Moreover, PPAR-α agonists have
been shown to ameliorate experimental autoimmune encephalomyelitis (EAE) in mice, suggesting that they could provide a
therapy for human autoimmune diseases such as multiple sclerosis.
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1. PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTORS (PPARs)
Peroxisome proliferator-activated receptors (PPARs) are
members of the steroid hormone nuclear receptor super-
family. So far, there are three isoforms that have been
identiﬁed and cloned, including PPAR-α,P P A R - β/δ,a n d
PPAR-γ, and they exhibit diﬀerent tissue distribution as well
as diﬀerent ligand speciﬁcities. PPAR-α is mainly expressed
in hepatocytes, cardiac myocytes, and proximal tubular
epithelial cells of the kidney. PPAR-γ expression occurs in
adipose tissues and colonic mucosal epithelium. PPAR-δ is
highly expressed in the placenta and large intestine. They can
be activated by polyunsaturated fatty acids [1–4].
PPARs are ligand-activated nuclear receptors and they
have been extensively studied in the regulation ofgenes
involved in glucose and lipid metabolism. They have been
thought to play an important role in the regulation of lipid
metabolism, energy balance, inﬂammation, artherosclerosis
and glucose control. Like other nuclear receptor family
members,allthreemembersofthePPARfamilyhavedistinct
functional domains responsible for ligand binding, DNA
binding, and coactivator/corepressor binding. They bind to
direct repeat 1 (DR1) elements or peroxisome proliferators
response elements (PPREs) in the promoter region of target
genes and drive the transcription of these target genes [1].
RecentstudieshaveshownthatPPARs,includingPPAR-α
and γ, play a very important role in the regulation of inﬂam-
matory responses, through mechanisms involving trans-
activation or transrepression of gene expression through
activation of transcription factors, including NF-κB, AP1,
and NFAT. In this review, we will focus on the regulation
of PPAR-α on immune responses and their agonists as a
potential treatment for autoimmune demyelinating diseases
such as multiple sclerosis.
Approximately 350000 people in the United States have
physician-diagnosed multiple sclerosis (MS) [5]. It is the
leading cause of neurologic disability in the United States
in young adults after trauma, thus most patients suﬀer
from the eﬀects of MS for most of their adult life. The
cause of MS remains unknown. An autoimmune process
for MS is hypothesized because it shares characteristics of2 PPAR Research
inﬂammation and demyelination with its animal model,
EAE. Epidemiologic studies and studies examining the
disease in identical twins also suggest that both environment
and genetics inﬂuence expression of the disease and play
a role in disease pathogenesis [6]. There are now six
drugs approved for use in the treatment of MS by the
FDA, however none of these agents are a cure for the
disease, so the need for better treatment strategies for MS
remains [7–10]. In addition, the unfortunate expression
of progressive multifocal leukoencephalopathy (PML) in MS
patients treated with nataluzimab highlights the need for
medications with a proven safety record [11–13].
Several animal models have been used to study MS.
In some of these models, disease is induced by viruses,
such as Theiler’s virus or Borna disease virus [14]. Of
the EAE models, the most commonly studied are those
established in the Lewis rat and in several susceptible mouse
strains. Murine EAE results in a relapsing-remitting disease,
similar to the early phase of disease for most MS patients,
whereas EAE in the Lewis rat is a monophasic illness. In
chronic murine EAE, the pathology observed in the white
matter shows much more demyelination than the Lewis
rat model, again being more reminiscent of the pathology
seen in the CNS of patients with MS. With the advent
of transgenic and homologous recombination technology,
it is increasingly clear that many powerful molecular tools
are becoming available to study the immune response in
pathologic processes such as EAE.
2. REGULATION OF IMMUNE RESPONSES BY PPAR-α
2.1. PPAR-αexpressioninimmunecells
PPAR-αispredominantlyexpressedintissuesexhibitinghigh
catabolicratesoffattyacids(liver,heart,kidney,andmuscle).
However, recent studies have shown that it is also expressed
in immune cells.
Monocytesandmacrophages
Chinetti et al. [15] showed that PPAR-α is expressed in
undiﬀerentiated monocytes and in diﬀerentiated human
monocyte-derived macrophages. PPAR-α is constitutively
expressed in the cytoplasm, whereas PPAR-γ is predomi-
nantly localized in the nucleus. They both were shown to be
transcriptionally active after ligand binding to their recep-
tors. Both PPAR-α and PPAR-γ ligands induce apoptosis
of macrophages following activation with tumor necrosis
factor-α/interferon-γ.
TandBlymphocytes
PPAR-α has been reported to be expressed in T and B
lymphocytes [16, 17] .J o n e se ta l .[ 16] demonstrated that
T and B lymphocytes constitutively express PPAR-α and
PPAR-γ.P P A R - α is the predominant isoform expressed in
lymphocytes, whereas PPAR-γ dominates in all cell types
of the myeloid lineage. However, PPAR-α and PPAR-γ
are diﬀerentially expressed following lymphocyte activa-
tion. PPAR-α expression was downregulated following T-
cell activation while PPAR-γ expression increased under
the same activating conditions. Exposure to speciﬁc ligand
determined that PPAR-α in lymphocytes eﬀectively transac-
tivates a peroxisome proliferator response element (PPRE)
reporter construct. Ligand activation of lymphocyte PPAR-
α antagonized NF-κB. These observations suggested that a
functional PPAR-α exists within T cells and B lymphocytes.
Langerhanscells
Epidermal Langerhans cells (LCs) play a pivotal role in
initiating and maintaining primary immune responses in the
skin. Dubrac et al. [18] showed that PPAR-α is expressed in
immature LC and downregulated in mature LC. Pharmaco-
logic PPAR-α activation inhibits LC maturation, migratory
capacity, cytokine expression, and the ability to drive T-
cell proliferation. Moreover, PPAR-α activation inhibits NF-
κB but not stress-activated protein kinase/JNK, p38MAPK,
and ERK1/2. This study suggested that PPAR-α activation
by endogenous ligands may provide a molecular signal that
allows LC to remain in an immature state.
2.2. PPAR-αregulationofinﬂammation
andcytokineproduction
The study of PPAR-α deﬁcient mice revealed the relationship
between PPAR-α and inﬂammation. Devchand et al. [19]
demonstrated that lack of PPAR-α activity increases inﬂam-
matory responses. They showed that inﬂammation due to
inﬂammatory agents, including arachidonic acid and LTB4,
is prolonged in PPAR-α deﬁcient mice as compared to wild-
type mice. The β and γ PPAR subtypes did not compensate
for a lack of PPAR-α in an LTB4-mediated inﬂammatory
response.
Delerive et al. [20] showed another possible mechanism
ofPPAR-αregulatinginﬂammation.Theydemonstratedthat
PPAR-α negatively regulates the vascular inﬂammatory gene
response by negative cross-talk with the transcription factors
NF-κB and AP-1. They showed that aortic explants isolated
from PPAR-α-null mice display an exacerbated response to
inﬂammatory stimuli, such as lipopolysaccharide (LPS), as
demonstrated by increased IL-6 secretion.
Cytokines are one of the major factors directing T-cell
diﬀerentiation and play an important role in the patho-
genesis of autoimmune diseases. Recent studies have shown
that PPAR-α regulates the expression of cytokines which are
critical in autoimmune disease (see below). Splenocytes har-
vested from PPAR-α agonist, WY14,643, fed and pMOG(35–
55) immunized mice showed impaired production of IFN-
γ,I L - 6 ,a n dT N F - α despite similar proliferative responses,
following in vitro restimulation with pMOG(35–55). It was
also observed that IL-4 expression in cultures of mitogen-
activated splenocytes was increased [21].
Lee et al. [22] reported that the PPAR-α agonist, Fenoﬁ-
brate, repressed IL-17 and interferon-gamma expression and
improved colitis in IL-10-deﬁcient mice. PPAR-α was found
to be expressed in lymphocytes, macrophages, and crypt
and surface epithelial cells of the colon. Colonic expressionYuhong Yang et al. 3
of interferon-gamma and IL-17 genes was decreased in
IL-10 deﬁcient mice, when the mice were treated with
fenoﬁbrate. Fenoﬁbrate also repressed interferon-gamma
and IL-17 expression in isolated T cells, the expression of
the genes encoding the chemokines, CXCL10, CCL2, and
CCL20, and repressed CXCL10 gene promoter activity in
tumor necrosis factor-alpha-treated HT-29 cells.
Jones et al. [23] reported that unliganded PPAR-α sup-
pressed T-bet expression and decreased IFN-γ production
in T cells. They demonstrated that activated CD4(+) T
cells lacking PPAR-α produce increased levels of IFN-γ,
but signiﬁcantly lower levels of IL-2 when compared with
activated wild-type CD4(+) T cells.
Another study by Dasgupta et al. [24] suggested that
PPAR-α increased the activity of GATA-3 and inhibited
expression of T-bet, which would be in agreement with prior
studies which showed that PPAR-α agonists increased IL-4
production by T cells. Interestingly, this study also suggested
that the PPAR-α agonist gemﬁbrozil could inhibit clinical
signs of EAE in mice deﬁcient in PPAR-α, with concomitant
upregulationofIL-4andinhibitionofIFN-γ [24].Thisstudy
did not indicate whether the same changes in T-bet and
GATA-3 expression also occurred in PPAR-α deﬁcient mice.
Delerive et al. [20] showed ﬁbrate treatment represses
IL-6 mRNA levels in LPS-stimulated aortas of PPAR-α
wild-type, but not of PPAR-α-null mice, demonstrating a
role for PPAR-α in this ﬁbrate action. In human aortic
smooth muscle cells, ﬁbrates inhibit IL-1-induced IL-6 gene
expression.
2.3. Possiblemechanisms
Like other transcription factors, PPARs are able to posi-
tively regulate gene expression by binding to PPRE as a
heterodimer with the retinoic acid X receptor (RXR). In
the unliganded state, PPARs are associated with a nucle-
arreceptor corepressor. In addition, heat shock protein-90
and the hepatitis virus B X-associated protein 2 have been
shown to associate with PPAR-α and negatively regulate
subsequent gene activation [25, 26]. Upon activation, the
PPARs undergo a conformational change that results in
the dissociation from the corepressor, enabling the PPAR
to bind nuclear receptor coactivators. These coactivators
then act to reorganize the chromatin templates allowing the
basal transcription machinery to gain access to the promoter
regions driving transcription of target genes.
In our lab, we have investigated the mechanism by which
the PPAR-α agonist gemﬁbrozil induces immune deviation
and protects mice from EAE. Similar to the studies by Das-
gupta[24],wedemonstratedthattreatmentwithgemﬁbrozil
increasesGATA-3anddecreasesT-betexpressioninvitroand
directly ex-vivo. These changes correlated with an increase in
nuclear PPAR-α expression. Moreover, the protective eﬀects
of gemﬁbrozil in EAE were shown to be partially dependent
on IL-4 and to occur in a receptor-dependent manner.
PPAR-α was shown to regulate the IL-4 and IL-5 genes and
bound the IL-4 promoter in the presence of steroid receptor
coactivator-1 (SRC-1), suggesting transactivation of the IL-4
gene (Figure 1)[ 27].
PPARs cannot only induce but also repress gene
transcription. One recent study showed a sumoylation-
dependent pathway mediating transrepression of inﬂam-
matory response genes by PPAR-γ in macrophages [28].
The initial step of this pathway involves ligand-dependent
sumoylation of the PPAR-γ ligand-binding domain, which
targets PPAR-γ to nuclear receptorcorepressor (NCoR)-
histone deacetylase-3 (HDAC3) complexes on inﬂammatory
gene promoters. This in turn prevents recruitment of the
ubiquitylation/19S proteasome machinery that normally
mediates the signal-dependent removal of corepressor com-
plexes required for gene activation. As a result, NCoR
complexes are not cleared from the promoter and target
genes are maintained in a repressed state. This mechanism
provides an explanation for how an agonist-bound nuclear
receptor can be converted from an activator of transcription
to a promoter-speciﬁc repressor of NF-κBt a r g e tg e n e s .
However, so far there is no evidence showing that PPAR-α
is able to repress target genes by this sumoylation-dependent
pathway.
Activated PPAR-α has been demonstrated to exert anti-
inﬂammatory activities through its ability to antagonize
other signaling pathways, in part through the interaction
with other transcription factors, including NF-κB, AP-1, and
STATs (see below).
Spencer et al. [29] have demonstrated that therapeutic
treatment of aged mice with PPAR-α activating agents
corrected abnormal nuclear NF-κB activity, redu ced lipid
peroxide levels, and eliminated the dysregulated expression
of cytokines and other genes under NF-κBc o n t r o l .
Delerive et al. showed activation of PPAR-α represses
both c-Jun- and p65-induced transcription of the human
IL-6 promoter. Glutathione S-transferase (GST) pull-down
experiments demonstrated that PPAR-α physically interacts
with c-Jun, p65, and CBP [20]. They further showed that
ﬁbrates, synthetic PPAR-α activators, induced the expression
of the inhibitory protein IκBα in human aortic smooth
muscle cells as well as in primary human hepatocytes. They
demonstrated that ﬁbrates induced IκBα in liver in vivo
and that this action required PPAR-α. Furthermore, ﬁbrate
treatment induced IκBα protein expression in the cytoplasm
and also enhanced IL-1β-induced accumulation of IκBα
p r o t e i ni nt h en u c l e u s[ 30]. These actions of ﬁbrates on IκBα
expression were accompanied by a decrease in NF-κBD N A
binding activity. They further demonstrated that induction
of IκBα gene transcription by PPAR-α is DNA binding-
independent. They demonstrated that PPAR-α potentiates
p65-stimulated IκBα transcription in a ligand-dependent
manner. PPAR-α activation of IκBα transcription requires
the NF-κB and Sp1 sites within the IκBα promoter. PPAR-
α activation enhances the occupancy of the NF-κBr e s p o n s e
element in IκBα promoter in vivo. VDR-interacting protein
205(DRIP205)isrequiredtoregulateIκBαpromoteractivity
[31].
PPAR-α was also found to negatively regulate the tran-
scription of T-bet. T-bet is a key regulator of the IFNγ
gene in Th1 cells. The induction of T-bet expression in
CD4(+)Tcellswasdeterminedtobepositivelyinﬂuencedby
p38 mitogen-activated protein (MAP) kinase activation, and4 PPAR Research
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Figure 1:AmodelforPP AR -α-mediatedprotectioninEAE.InthepresenceofPPAR-αagonists,PPAR-αheterodimerizeswithRXR,dissociates
from its nuclear corepressor complex, associates with a coactivator complex, and binds to PPREs in the promoter region of IL-4 and/or
IL-5. The transactivation of IL-4/IL-5 leads to increased expression of GATA-3 which in turn results in decreased T-bet expression and
downregulation of the Th1/Th17 inﬂammatory response. This shift in the immune response to a Th2-like phenotype results in amelioration
of EAE.
the presence of unliganded PPAR-α eﬀectively suppressed
the phosphorylation of p38 MAP kinase. The activation of
PPAR-α with highly speciﬁc ligands relaxed its capacity to
suppress p38 MAP kinase phosphorylation and promoted
T-bet expression [23]. This observation conﬂicts with the
observation of Dasgupta [24]a n do u ro w nw o r k .
Lee et al. found that four PPAR-α activators sup-
pressed lipopolysaccharide-stimulated STAT1 phosphoryla-
tion and nuclear factor binding to γ-interferon-activated
sequence/interferon-α-stimulated response element sites
known to contain STAT binding sites. PPAR-α activators also
suppressed lipopolysaccharide-stimulated tumor necrosis
factor-α and monocyte chemoattractant protein-1 transcrip-
tion and release [32].
In addition to PPAR-α dependent transcriptional regula-
tion, Selim et al. [33] showed that ﬁbrates upregulate TRB3
in lymphocytes independent of PPAR-α by augmenting
CCAAT/enhancer-binding protein β (C/EBP-β) expression.
They demonstrated that ﬁbrates upregulate TRB3 expression
(a protein that interferes with insulin-induced activation of
AKT), in mitogen-activated lymphocytes of both wild type
and knockout mice, suggesting that upregulation of this
protein occurs in a PPAR-α-independent manner.
Dasgupta et al. [24] showed gemﬁbrozil inhibited the
encephalitogenicity of MBP-primed T cells and switched the
immune response from a Th1 to a Th2 proﬁle independent
of PPAR-α. Gemﬁbrozil consistently inhibited the expression
and DNA-binding activity of T-bet, and stimulated the
expression and DNA-binding activity of GATA-3, a key
regulator of IL-4. Gemﬁbrozil treatment decreased the
number of T-bet-positive T cells and increased the number
of GATA-3-positive T cells in the spleens of donor mice.
Gemﬁbrozil was shown to have an inhibitory eﬀect on the
invasion of T-bet-positive T cells into the spinal cord of EAE
mice. Furthermore, they demonstrate that the diﬀerential
eﬀect of gemﬁbrozil on the expression of T-bet and GATA-
3 was due to its inhibitory eﬀect on NO production.
3. PPAR ALPHA AND AUTOIMMUNE
ENCEPHALOMYELITIS
Organ-speciﬁc autoimmune diseases, such as multiple scle-
rosis (MS) and its animal model, are mediated by IFN-γ
and/or IL-17 producing CD4 T helper cells. Since PPAR-
α regulates inﬂammation and cytokine production, PPAR-
α agonists have been tested as a potential treatment for
autoimmune diseases.
Lovett-Racke et al. [34] demonstrated that PPAR-α
agonists can be used as a therapy for autoimmune disease.
They demonstrated that PPAR-α agonists can increase the
production of the Th2 cytokine, IL-4, and suppress prolif-
eration by TCR transgenic T cells speciﬁc for the myelin
basic protein Ac1-11, as well as reduce NO production by
microglia. Oral administration of gemﬁbrozil and fenoﬁ-
brate inhibited clinical signs of experimental autoimmune
encephalomyelitis.Moreimportantly,gemﬁbrozilwasshown
to shift the cytokine secretion of human T-cell lines by
inhibiting IFN-γ andpromotingIL-4secretion.Theseresults
suggest that PPAR-α agonists, such as gemﬁbrozil and
fenoﬁbrate, may be attractive candidates for use in human
inﬂammatory conditions such as multiple sclerosis.
In another study, Dasgupta et al. [24] demonstrated that
gemﬁbrozil ameliorates relapsing-remitting EAE indepen-
dent of PPAR-α. They showed that clinical signs of EAE,Yuhong Yang et al. 5
inﬁltration of mononuclear cells, and demyelination were
signiﬁcantly lower in mice receiving gemﬁbrozil, suggesting
gemﬁbrozil may ﬁnd therapeutic use in multiple sclerosis.
Interestingly, PPAR-α expression in T cells was suggested
to mediate gender diﬀerences in development of T-cell-
mediatedautoimmunity.Dunnetal.[35]showedthatPPAR-
α is more abundant in male as compared with female
CD4(+) cells and that its expression is sensitive to androgen
levels. Upon induction of EAE, male PPAR-α (−/−)m i c e
developed more severe clinical signs than females. These
results suggest that males are less prone to develop Th1-
mediated autoimmunity because they have higher T-cell
expression of PPAR-α.
Xu et al. [36] investigated the eﬀects of PPAR-α agonists
on primary mouse microglia, a cell type implicated in the
pathology of MS and EAE. They demonstrated that PPAR-
α agonists inhibited the secretion of IL-1β,T N F - α,I L - 6 ,
and IL-12 p40 and the chemokine MCP-1 by LPS-stimulated
microglia. Retinoid X receptors (RXRs) physically interact
with PPAR-α receptors, and the resulting heterodimers
regulate the expression of PPAR-responsive genes. They
demonstrated that the PPAR-α agonists ciproﬁbrate, fenoﬁ-
brate, gemﬁbrozil, and WY14,643 inhibited NO production
by stimulated microglia in a dose-dependent manner. Fur-
thermore,acombinationof9-cisRAandthePPAR-αagonist
fenoﬁbrate cooperatively inhibited NO production by these
cells. This study suggested that PPAR-α and RXR agonists
might have beneﬁt as a therapy in MS, where activated
microglia are believed to contribute to disease pathology.
Other than microglia cells, they also investigated the
eﬀects of PPAR-α agonists on primary mouse astrocytes
[37]. They observed similar inhibition on cytokine pro-
duction by PPAR-α agonists. PPAR-α agonists inhibited the
secretion of TNF-α,I L - 1 β, and IL-6 by LPS-stimulated
astrocytes. Additionally, fenoﬁbrate inhibited NF-κBD N A
binding activity, suggesting a mechanism by which PPAR-α
agonists may regulate the expression of genes encoding these
proinﬂammatory molecules. Retinoid X receptors (RXRs)
physically interact with PPAR-α receptors, and the resulting
heterodimers regulate the expression of PPAR-responsive
genes.
They further demonstrated that fenoﬁbrate suppression
of EAE was associated with decreased expression of IL-
12 family cytokine mRNAs as well as mRNAs encod-
ing TLR4, CD14, and MyD88. They showed that the
PPAR-α agonist fenoﬁbrate inhibited the secretion of IL-
12p40, IL-12p70 (p35/p40), IL-23 (p19/p40), and IL-27p28
by lipopolysaccharide-stimulated microglia. Furthermore,
fenoﬁbrate inhibited microglial expression of CD14 which
plays a critical role in TLR signaling [38].
4. CONCLUSION
The functional expression of PPAR-α by several immune
cell types suggests that this receptor may play a very
important role in regulation of immune responses. Recent
studies demonstrate that PPAR-α regulates diﬀerent aspects
of immune responses, including inﬂammation and cytokine
production. Moreover, several studies showed evidence that
PPAR-α agonists have potent eﬀects in regulating immune
responses and ameliorating EAE. However, the detailed
mechanisms have not been completely delineated. Better
understanding of the molecular mechanism by which PPAR-
α regulates cytokine pathways in immune cells will be very
helpful for further development of PPAR-α agonists as a
therapy for autoimmune diseases.
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